For decades, Alzheimer’s has been a disease without a cure. But now, researchers at the National Institutes of Health may have found a way to prevent the often slow and difficult decline the illness inflicts on people’s lives. People who are genetically predisposed to Alzheimer’s but who don’t have any symptoms will be given Crenezumab, a medication that breaks up plaque that settles on the brain, to see if it keeps dementia from developing. The $100 million study will run for five years, but could see results in as little as two years.
